Drug Profile
Zibotentan - AstraZeneca
Alternative Names: AZD-4054; ZD-4054Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; University Medical Center Groningen
- Class Antineoplastics; Oxadiazoles; Pyrazines; Pyridines; Small molecules; Sulfonamides
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver cirrhosis; Renal failure
- Phase I Liver failure
- Discontinued Breast cancer; Colorectal cancer; Heart failure; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 03 Nov 2023 Efficacy data from the phase-II ZENITH-CKD trial in Renal failure released by AstraZeneca
- 03 Nov 2023 AstraZeneca plans a phase-III trial for Renal failure in Q4 2023
- 01 Jun 2023 AstraZeneca completes the ZENITH-CKD trial in Renal failure in Ukraine, Spain, South Africa, Slovakia, Poland, Netherlands, Malaysia, Japan, Italy, Hungary, Georgia, Denmark, Croatia, Bulgaria, Canada, Brazil, Australia, Argentina (PO) (NCT04724837) (EudraCT2020-004101-32)